Abstract
An updated, final analysis from the phase III FLAURA study showed that compared with older EGFR inhibitors, the third-generation drug osimertinib was better tolerated and significantly improved overall survival among patients newly diagnosed with EGFR-mutant non–small cell lung cancer.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst October 7, 2019
doi: 10.1158/2159-8290.CD-NB2019-120
Osimertinib Holds Its Own in NSCLC
Jump to section
Advertisement